T. Rowe Price Associates
STOK icon

T. Rowe Price Associates’s Stoke Therapeutics STOK Stock Holding History

T. Rowe Price Associates’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63M Buy
1,934,171
+1,561,837
+419% +$51.2M 0.01% 715
2025
Q4 		$11.8M Buy
372,334
+321,071
+626% +$9.65M ﹤0.01% 1193
2025
Q3 		$1.21M Buy
51,263
+7,528
+17% +$129K ﹤0.01% 1975
2025
Q2 		$497K Buy
43,735
+4,637
+12% +$44K ﹤0.01% 2304
2025
Q1 		$261K Buy
39,098
+1,643
+4% +$15.3K ﹤0.01% 2528
2024
Q4 		$414K Buy
37,455
+2,215
+6% +$27.2K ﹤0.01% 2365
2024
Q3 		$434K Buy
35,240
+194
+0.6% +$2.75K ﹤0.01% 2320
2024
Q2 		$474K Buy
35,046
+3,615
+12% +$48.8K ﹤0.01% 2210
2024
Q1 		$425K Buy
31,431
+1,642
+6% +$9.95K ﹤0.01% 2275
2023
Q4 		$157K Hold
29,789
– – ﹤0.01% 2614
2023
Q3 		$118K Sell
29,789
-329,133
-92% -$2.16M ﹤0.01% 2629
2023
Q2 		$3.82M Sell
358,922
-18,879
-5% -$201K ﹤0.01% 1260
2023
Q1 		$3.15M Sell
377,801
-17,306
-4% -$156K ﹤0.01% 1311
2022
Q4 		$3.65M Sell
395,107
-17,236
-4% -$179K ﹤0.01% 1258
2022
Q3 		$5.29M Sell
412,343
-4,378
-1% -$69.8K ﹤0.01% 1192
2022
Q2 		$5.5M Sell
416,721
-7,142
-2% -$109K ﹤0.01% 1413
2022
Q1 		$8.92M Sell
423,863
-14,384
-3% -$288K ﹤0.01% 1383
2021
Q4 		$10.5M Buy
438,247
+100,665
+30% +$2.4M ﹤0.01% 1401
2021
Q3 		$8.59M Sell
337,582
-49,841
-13% -$1.39M ﹤0.01% 1438
2021
Q2 		$13M Sell
387,423
-235,769
-38% -$8.33M ﹤0.01% 1382
2021
Q1 		$24.2M Sell
623,192
-126,434
-17% -$7.2M ﹤0.01% 1230
2020
Q4 		$46.4M Buy
749,626
+379,533
+103% +$17.4M ﹤0.01% 986
2020
Q3 		$12.4M Sell
370,093
-21,265
-5% -$607K ﹤0.01% 1250
2020
Q2 		$9.33M Sell
391,358
-36,164
-8% -$859K ﹤0.01% 1309
2020
Q1 		$9.79M Sell
427,522
-60,991
-12% -$1.51M ﹤0.01% 1230
2019
Q4 		$13.8M Buy
488,513
+106,200
+28% +$2.67M ﹤0.01% 1258
2019
Q3 		$8.22M Buy
382,313
+5,413
+1% +$151K ﹤0.01% 1319
2019
Q2 		$11M Buy
+376,900
New +$10.1M ﹤0.01% 1298

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Associates's STOK Position: Q1 2026 in Review

T. Rowe Price Associates increased its Stoke Therapeutics (STOK) stake by 419% in Q1 2026, buying an estimated $51.2M and bringing the position to 1,934,171 shares worth $63M. The position accounts for 0.01% of the portfolio, ranked #715.

T. Rowe Price Associates first reported a position in STOK in Q2 2019 and has held it in 28 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • T. Rowe Price Associates held 1,934,171 shares of Stoke Therapeutics worth $63M as of Q1 2026.
  • T. Rowe Price Associates bought 1,561,837 Stoke Therapeutics shares in Q1 2026, an estimated $51.2M.
  • Stoke Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #715 holding.
  • T. Rowe Price Associates first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.